SUBSTITUTED HETEROCYCLES AS THERAPEUTIC AGENTS FOR TREATING CANCER
    1.
    发明申请
    SUBSTITUTED HETEROCYCLES AS THERAPEUTIC AGENTS FOR TREATING CANCER 审中-公开
    作为治疗癌症的治疗药物的替代治疗剂

    公开(公告)号:US20130211079A1

    公开(公告)日:2013-08-15

    申请号:US13841648

    申请日:2013-03-15

    摘要: MDM2 and MDM4 proteins prevent apoptosis of cancer cells by negatively regulating the transcription factor p53. Compounds according to Formula I are selective antagonists of MDM2 and MDM4 proteins, disrupting the p53/MDM2 and p53/MDM4 complex. These compounds therefore are candidate therapeutics for treating cancer as well as other cell proliferative disease states.

    摘要翻译: MDM2和MDM4蛋白通过负调节转录因子p53阻止癌细胞的凋亡。 根据式I的化合物是MDM2和MDM4蛋白的选择性拮抗剂,破坏p53 / MDM2和p53 / MDM4复合物。 因此,这些化合物是用于治疗癌症以及其它细胞增殖性疾病状态的候选治疗剂。